Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Via News Knowledge File

AbbVie Inc.

organization80% conf.·synced Aug 13, 2026

Biopharmaceutical company based in North Chicago, Illinois, developing oncology and hematology therapeutics

48
sourced metrics
521
relationships
20
stated objectives
5
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Stock Price
248.76USD
Aug 12, 2026reference only
Price 52 Week High
263.30USD
Aug 12, 2026reference only
Stock Return Ytd
8.5%
Aug 12, 2026reference only
Price 52 Week Low
197.38USD
Aug 12, 2026reference only
Net Income
3613000000.0USD
Jun 30, 2026reference only
Capex
587000000.0USD
Jun 30, 2026reference only
Cash
6569000000.0USD
Jun 30, 2026reference only
Stockholders Equity
-5935000000.0USD
Jun 30, 2026reference only
Cost Of Revenue
4291000000.0USD
Jun 30, 2026reference only
Total Assets
135115000000.0USD
Jun 30, 2026reference only
Revenue
16990000000.0USD
Jun 30, 2026reference only
Eps
2.03USD_per_share
Jun 30, 2026reference only
Operating Income
6432000000.0USD
Jun 30, 2026reference only
Operating Cash Flow
7265000000.0USD
Jun 30, 2026reference only
Consecutive Dividend Increases
53years
May 25, 2026source
Mid Late Stage Clinical Trials
60programs
May 25, 2026source
Pipeline Total Programs
90programs
May 25, 2026source
Portfolio Weight In Xlv
7.09percent
May 18, 2026source

Stated objectives

Develop and commercialize 35+ investigational medicines in multiple clinical trials across hematologic cancers

source
target: 35 stated

Pursue additional international regulatory approvals for the R/R FL indication

source
stated

Evaluate epcoritamab as monotherapy and in combination across lines of therapy in a range of hematologic malignancies through four ongoing Phase 3 trials

source
stated

Achieve adjusted diluted EPS for 2025

source
target: 12.12 to 12.32 USD by 2025-12-31 00:00:00stated

Achieve high single-digit compound annual revenue growth rate for ex-Humira platform

source
target: high single-digit percent by 2029-12-31 00:00:00stated

Achieve combined sales of immunology duo

source
target: 27 billion USD by 2027-12-31 00:00:00stated

Raised full-year earnings guidance

source
target: $10.61-$10.65 EPS by 2025-12-31 00:00:00stated

High single-digit CAGR through 2029

source
target: high single-digit percent CAGR by 2029-01-01 00:00:00stated

Drive long-term growth through early-stage pipeline development

source
stated

Return to robust revenue growth following Humira LOE

source
by 2025-01-01 00:00:00stated

Relationship graph · 521 connections

Developed by
245
Competes with
48
Covered by
41
headquartered in
30
Employs
27
regulates
18
acquired by
12
Invested in
10

Via News coverage

Four Oncology Drugs Face FDA PDUFA Decisions in 2026, Stacking Binary Catalyst Risk Into a Narrow Window
June 19, 2026
FDA H2 2026 Oncology Docket Packs Four Major Decisions Into One Catalyst Window
June 17, 2026
Jade Biosciences JADE301 Phase 1 Trial Set for March 2027 Start in Autoimmune Space
February 21, 2026
Dividend Stocks Offer Steady Income but Come with Risks
January 19, 2026
AbbVie Strikes Deal to Cut Drug Prices, Boost U.S. R&D Investment
January 13, 2026
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →